Amphastar Pharmaceuticals, Inc. (AMPH) 股票分析

公司概述

Amphastar Pharmaceuticals, Inc. operates as a bio-pharmaceutical entity dedicated to the development, manufacturing, marketing, and sales of generic and proprietary injectable, inhalation, and intranasal products across the United States, China, and France. Within the broader healthcare sector, the company specifically functions within the drug manufacturers - specialty & generic industry, a segment focused on producing affordable medication alternatives and specialized delivery systems. The organization employs a workforce of 1,976 individuals and holds a total market capitalization of $959.02 million. With annual revenue reaching $719.89 million, these valuation figures position Amphastar as a mid-cap player with a substantial operational footprint, indicating a company that has secured significant market share and revenue streams while maintaining a manageable scale relative to large-cap pharmaceutical giants.

财务健康

The company generated revenue of $719.89 million over the trailing twelve months, resulting in a net income of $98.09 million and an EBITDA of $220.20 million. The substantial gap between revenue and net income highlights a significant cost structure where operating expenses, including cost of goods sold and administrative costs, consume approximately 86.4% of total revenue before reaching the bottom line. Free cash flow stands at $81.37 million, which demonstrates the company's ability to generate liquidity from its core operations, providing financial flexibility to fund research initiatives, repay obligations, or potentially acquire assets without immediate reliance on external financing. Profitability is measured across three key margins: a gross margin of 49.5%, an operating margin of 19.4%, and a profit margin of 13.6%, indicating that while the manufacturing and sales efficiency is moderate, the final profitability is impacted by substantial operating expenditures. On the balance sheet, the company holds $282.81 million in cash against $656.00 million in debt, resulting in a debt-to-equity ratio of 83.16, which suggests a leveraged capital structure where liabilities significantly outweigh equity. Despite the debt load, the current ratio of 4.02 indicates strong short-term liquidity, as current assets are more than four times current liabilities, ensuring the ability to meet immediate financial obligations. Return on equity is calculated at 12.9% and return on assets at 6.4%, metrics that reveal management's effectiveness in generating profits from shareholders' investments and utilizing the asset base efficiently, respectively.

估值评估

Valuation metrics for Amphastar show a trailing P/E ratio of 10.28 and a forward P/E of 6.03. The notable difference between the trailing and forward P/E implies that the market expects earnings growth in the future, as investors are willing to pay a lower multiple for expected future earnings compared to historical performance. The price-to-book ratio is 1.21, indicating that the stock trades at a slight premium over its book value, reflecting market confidence in the company's intangible assets and future earning potential beyond its net asset value. Alternative valuation measures include a price-to-sales ratio of 1.33 and an EV/EBITDA of 6.00, suggesting the company is valued reasonably relative to its sales volume and earnings before interest, taxes, depreciation, and amortization. The stock has traded within a 52-week range with a high of $31.26 and a low of $17.03; based on the provided data, the current valuation context sits within this historical band, reflecting market volatility and sentiment shifts over the past year. The beta value of 0.91 indicates that the stock's price volatility is slightly lower than the broader market, suggesting it may act as a relatively defensive position within the healthcare sector during periods of market turbulence.

Growth & Income

Amphastar reported a revenue growth year-over-year of -1.8% and an earnings growth year-over-year of -31.0%, indicating a contraction in both top-line sales and profitability. Earnings are declining at a much faster rate than revenue, which implies that the company is facing significant pressure on margins or has incurred non-recurring costs that are disproportionately affecting the bottom line compared to revenue decline. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders and instead retains earnings to reinvest into growth initiatives, such as R&D or capacity expansion. The overall growth and income profile for Amphastar currently reflects a phase of contraction and reinvestment rather than distribution, with the company prioritizing operational adjustments and market positioning over immediate shareholder returns through dividends.